Pfizer Inc. (PFE)
Pfizer Stock Falls to New 52-Week Low: Should You Buy the Dip?
PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors due to its sky-high dividend yield.
Pfizer: Anticipating A Game-Changer Soon
I reaffirm my Buy rating on Pfizer due to expected promising updates on danuglipron and strong capital efficiency metrics, despite the recent stock pullback. Pfizer's management is expected to announce danuglipron updates soon, potentially boosting investor sentiment and stock performance. Pfizer's cost reduction programs and revenue growth targets for CY25 remain on track, with EPS projected to more than double.
Pfizer: Best-In-Class Dividend Yield Together With Dirt Cheap Valuation
Pfizer's 7.5% dividend yield is safe due to revenue growth, cost efficiency, and a stronger balance sheet, making it a strong buy. Pfizer's innovation in R&D, including AI partnerships and new drug approvals, promises long-term market cap growth and a competitive edge. Defensive stocks like Pfizer are attractive amid market volatility, with the pharmaceutical sector being less vulnerable to economic cycles.
Is Pfizer (PFE) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna
In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (PFE 0.77%) and Moderna (MRNA 2.21%). These two vaccine makers made small fortunes thanks to their work in this space.
Is Pfizer Stock a Buy?
Pfizer's (PFE 0.77%) share price has fallen more than the S&P 500 so far this year. The big pharma stock is nearly 60% below its high set in late 2022.
Pfizer (PFE) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, Pfizer (PFE) stood at $24.70, denoting a +0.65% change from the preceding trading day.
PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters
Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.
Proxy adviser ISS recommends Pfizer shareholders to vote against CEO compensation
Institutional Shareholder Services is recommending Pfizer's investors to reject a management proposal on annual compensation for CEO Albert Bourla and other executives, the proxy adviser said on Wednesday.
PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo
The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of age in the EU.
European Commission approves Pfizer's RSV vaccine for adults at increased risk of disease
The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease, the company said on Tuesday.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
